Arcus Biosciences, Inc. (RCUS)
25.01
+0.04
(+0.16%)
USD |
NYSE |
Sep 28, 16:00
25.02
+0.01
(+0.04%)
After-Hours: 19:47
Arcus Biosciences Cash from Operations (Annual) : -482.00M for Dec. 31, 2025
Cash from Operations (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | -482.00M |
| December 31, 2024 | -170.00M |
| December 31, 2023 | -306.00M |
| December 31, 2022 | 438.00M |
| December 31, 2021 | -256.17M |
| Date | Value |
|---|---|
| December 31, 2020 | 111.17M |
| December 31, 2019 | -73.46M |
| December 31, 2018 | -43.00M |
| December 31, 2017 | -25.06M |
| December 31, 2016 | -12.94M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Annual) Benchmarks
| Halozyme Therapeutics, Inc. | 651.56M |
| AVITA Medical, Inc. | -31.20M |
| Iovance Biotherapeutics, Inc. | -302.41M |
| Editas Medicine, Inc. | -165.24M |
| Recursion Pharmaceuticals, Inc. | -371.81M |